Fisher & Paykel HealthcareASX:FPH +0.19%90 PS Ratio is 9.52 as of Jun. 30, 2026, which is 5% above its 10-year median of 9.04. GuruFocus rates ASX:FPH with a GF Score™ of 90/100 and a GF Value™ of A$36.41 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 804 Medical Devices & Instruments companies, Fisher & Paykel Healthcare ranks worse than 84.08% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Fisher & Paykel Healthcare's share price is A$32.05.
Fisher & Paykel Healthcare's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was A$3.37. Hence, Fisher & Paykel Healthcare's PS Ratio for today is 9.52.
The historical rank and industry rank for Fisher & Paykel Healthcare's PS Ratio or its related term are showing as below:
ASX:FPH'
s PS Ratio Range Over the Past 10 Years
Min: 5.76 Med: 9.04 Max: 18.86
Current: 9.99
During the past 13 years, Fisher & Paykel Healthcare's highest PS Ratio was 18.86. The lowest was 5.76. And the median was 9.04.
ASX:FPH's PS Ratio is ranked worse than 84.08% of 804
companies
in the Medical Devices & Instruments industry
Industry Median: 2.94
vs ASX:FPH: 9.99
During the past 12 months, the average Revenue per Share Growth Rate of Fisher & Paykel Healthcare was 80.10% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 12.70% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 0.10% per year.
During the past 10 years, the average Revenue per Share Growth Rate was 8.80% per year.
During the past 13 years, Fisher & Paykel Healthcare's highest 3-Year average Revenue per Share Growth Rate was 26.20% per year. The lowest was -8.50% per year. And the median was 10.30% per year.
Back to Basics: PS Ratio
Fisher & Paykel Healthcare (ASX:FPH) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Fisher & Paykel Healthcare PS Ratio Related Terms
Fisher & Paykel Healthcare PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Fisher & Paykel Healthcare's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fisher & Paykel Healthcare PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Fisher & Paykel Healthcare's PS Ratio distribution charts can be found below:
* The bar in red indicates where Fisher & Paykel Healthcare's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Fisher & Paykel Healthcare's Share Price of today is A$32.05.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Fisher & Paykel Healthcare's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was A$3.37.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Fisher & Paykel Healthcare (ASX:FPH) has a PS Ratio of 9.52 as of Jun. 30, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Fisher & Paykel Healthcare and its competitors. This is near median its historical median of 9.04. Over the past decade, Fisher & Paykel Healthcare's PS Ratio has ranged from 5.76 to 18.86. According to the industry distribution chart, Fisher & Paykel Healthcare ranks #676 out of 804 companies in the Medical Devices & Instruments industry, placing it in the top 84.1%.
Is Fisher & Paykel Healthcare's PS Ratio too high?
Fisher & Paykel Healthcare's current PS Ratio of 9.52 is near median its 10-year median of 9.04. Over the past 10 years, this metric has ranged from a low of 5.76 to a high of 18.86. The Medical Devices & Instruments industry median PS Ratio is 2.94. Fisher & Paykel Healthcare's value of 9.52 is 223.8% above this industry median. Based on the distribution chart, Fisher & Paykel Healthcare ranks #676 out of 804 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Fisher & Paykel Healthcare has a GF Score™ of 90/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Fisher & Paykel Healthcare's PS Ratio compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Fisher & Paykel Healthcare ranks #676 out of 804 companies for PS Ratio. This places Fisher & Paykel Healthcare in the lower half of its industry. The industry median PS Ratio is 2.94. Fisher & Paykel Healthcare's value of 9.52 is 223.8% above this benchmark. Historically, Fisher & Paykel Healthcare's own PS Ratio has ranged from 5.76 to 18.86 over the past decade. While the company's 10-year median is 9.04 vs. the industry median of 2.94, Fisher & Paykel Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Medical Devices & Instruments company?
The median PS Ratio among Medical Devices & Instruments companies is 2.94, based on 804 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fisher & Paykel Healthcare's current PS Ratio of 9.52 is 223.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Fisher & Paykel Healthcare and its competitors. For the Medical Devices & Instruments industry, the median PS Ratio is 2.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fisher & Paykel Healthcare's current PS Ratio is 9.52, which is near median its own 10-year median of 9.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fisher & Paykel Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare (ASX:FPH) is currently considered Modestly Undervalued. The stock's GF Value™ is A$36.41, compared to a current price of A$32.05 — trading 12% below its estimated fair value. The current PS Ratio is 9.52, which is near median its 10-year median of 9.04 and 223.8% above the Medical Devices & Instruments industry median of 2.94. Fisher & Paykel Healthcare's overall GF Score™ is 90/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Fisher & Paykel Healthcare (ASX:FPH), the current PS Ratio is 9.52 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fisher & Paykel Healthcare (ASX:FPH) Overvalued in 2026?
Based on GuruFocus' analysis, Fisher & Paykel Healthcare stock appears to be undervalued.
The current stock price of A$32.05 is trading 12% below its estimated GF Value™ of A$36.41.
GuruFocus considers Fisher & Paykel Healthcare to be Modestly Undervalued.
Key valuation signals for ASX:FPH:
PS Ratio: 9.52 (near median its 10-year median of 9.04)
GF Value™: A$36.41 vs. price of A$32.05 (12% below fair value)
Industry Position: 223.8% above the Medical Devices & Instruments median (#676 of 804)
No single metric tells the full story. See the ASX:FPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fisher & Paykel Healthcare is one of the three largest respiratory care device companies globally. It is the market leader in hospital use of humidifiers, masks, and related consumables, and the number three player in the at-home treatment of sleep apnea using respiratory devices. Both the hospital and homecare markets for respiratory devices are growing strongly in the developed markets in which Fisher & Paykel has a presence. The company earns roughly half of its revenue in North America, around a quarter in Europe, and approximately a fifth in Asia-Pacific. Fisher conducts its own R&D and has thousands of patents and pending applications. It manufactures in New Zealand, Mexico, and China, and has a multichannel distribution model.
90GF Score
Get the complete analysis for ASX:FPH
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:FPH has been successfully added to your 
